Arbutus Biopharma
ABUS
131 hedge funds and large institutions have $298M invested in Arbutus Biopharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 10 closing their positions.
761% more call options, than puts
Call options by funds: $11M | Put options by funds: $1.28M
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
39% more capital invested
Capital invested by funds: $215M → $298M (+$83.2M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
10% more funds holding
Funds holding: 119 → 131 (+12)
4.78% more ownership
Funds ownership: 46.47% → 51.25% (+4.8%)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$36.4M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.04M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.65M |
| 4 |
BlackRock
New York
|
+$3.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.1M |
Top Sellers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$9.43M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.55M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$5.51M |
| 4 |
CC
Centiva Capital
New York
|
-$3.9M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$323K |
ABUS Hedge Fund Activity: Q2 2024 in Review
131 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2024, worth a combined $298M — up 39% from $215M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ABUS positions and 10 closed out — a net gain of 13 holders — while 49 added to existing stakes and 30 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $36.4M. The largest seller was Woodline Partners, cutting an estimated $9.43M.
- 131 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2024, up from 119 in Q1 2024.
- Funds reported $298M of Arbutus Biopharma stock for Q2 2024, up 39% quarter-over-quarter.
- 23 funds opened new Arbutus Biopharma positions in Q2 2024 and 10 closed out, a net change of +13 holders.
- The largest Arbutus Biopharma buyer in Q2 2024 was Morgan Stanley, an estimated $36.4M added.
- The largest Arbutus Biopharma seller in Q2 2024 was Woodline Partners, an estimated $9.43M sold.
Based on aggregated 13F filings for Q2 2024.